| Variable . | APD (n = 20) . | CDI (n = 20) . | P Value . |
|---|---|---|---|
| Age at diagnosis, y | 30.7 ± 3.6 | 30.6 ± 2.8 | 0.98 |
| Number of APDs | 3.3 ± 0.2 | 3.4 ± 0.2 | 0.73 |
| Time since first APD, y, [median (IQR)] | 6.8 (4.3) | 12.3 (13.2) | 0.41 |
| Time since CDI, y, [median (IQR)] | NA | 13.3 (16.6) | 0.41 |
| Pituitary tumor | 19 (95.0) | 14 (70.0) | 0.09 |
| Pituitary disease | 0.46 | ||
| Nonfunctioning PA | 5 (25.0) | 4 (20.0) | |
| CP | 4 (20.0) | 5 (25.0) | |
| Prolactinoma | 2 (10.0) | 0 (0) | |
| Acromegaly | 2 (10.0) | 1 (5.0) | |
| Cushing syndrome | 3 (15.0 | 1 (5.0) | |
| Neurosarcoidosis | 0 (0) | 2 (10.0) | |
| Histiocytosis | 0 (0) | 1 (5.0) | |
| Chondrosarcoma | 2 (10.0) | 0 (0) | |
| Pituitary hypoplasia | 1 (5.0) | 1 (5.0) | |
| Pituitary stalk enlargement | 0 (0) | 2 (10.0) | |
| Germinoma | 0 (0) | 2 (10.0) | |
| Other | 1 (5.0) (medulloblastoma) | 1 (5.0) (Rathke cleft cyst) | |
| Macroadenoma | 16 (80.0) | 11 (55.0) | 0.55 |
| Surgery | 17 (85.0) | 13 (65.0) | 0.27 |
| Transsphenoidal surgery | 11 (55.0) | 9 (45.0) | |
| Craniotomy | 4 (20.0) | 4 (20.0) | |
| Both | 2 (10.0) | 0 (0) | |
| Radiotherapy | 15 (75.0) | 5 (35.0) | 0.03 |
| Pituitary deficiencies | 1.00 | ||
| Hypogonadism | 19 (95) | 19 (95) | |
| Adrenal insufficiency | 15 (75.0) | 16 (80.0) | |
| Central hypothyroidism | 18 (90.0) | 18 (90.0) | |
| GH deficiency | 13 (65.0) | 14 (70.0) | |
| GH deficiency not tested | 2 (10.0) | 1 (5.0) |
| Variable . | APD (n = 20) . | CDI (n = 20) . | P Value . |
|---|---|---|---|
| Age at diagnosis, y | 30.7 ± 3.6 | 30.6 ± 2.8 | 0.98 |
| Number of APDs | 3.3 ± 0.2 | 3.4 ± 0.2 | 0.73 |
| Time since first APD, y, [median (IQR)] | 6.8 (4.3) | 12.3 (13.2) | 0.41 |
| Time since CDI, y, [median (IQR)] | NA | 13.3 (16.6) | 0.41 |
| Pituitary tumor | 19 (95.0) | 14 (70.0) | 0.09 |
| Pituitary disease | 0.46 | ||
| Nonfunctioning PA | 5 (25.0) | 4 (20.0) | |
| CP | 4 (20.0) | 5 (25.0) | |
| Prolactinoma | 2 (10.0) | 0 (0) | |
| Acromegaly | 2 (10.0) | 1 (5.0) | |
| Cushing syndrome | 3 (15.0 | 1 (5.0) | |
| Neurosarcoidosis | 0 (0) | 2 (10.0) | |
| Histiocytosis | 0 (0) | 1 (5.0) | |
| Chondrosarcoma | 2 (10.0) | 0 (0) | |
| Pituitary hypoplasia | 1 (5.0) | 1 (5.0) | |
| Pituitary stalk enlargement | 0 (0) | 2 (10.0) | |
| Germinoma | 0 (0) | 2 (10.0) | |
| Other | 1 (5.0) (medulloblastoma) | 1 (5.0) (Rathke cleft cyst) | |
| Macroadenoma | 16 (80.0) | 11 (55.0) | 0.55 |
| Surgery | 17 (85.0) | 13 (65.0) | 0.27 |
| Transsphenoidal surgery | 11 (55.0) | 9 (45.0) | |
| Craniotomy | 4 (20.0) | 4 (20.0) | |
| Both | 2 (10.0) | 0 (0) | |
| Radiotherapy | 15 (75.0) | 5 (35.0) | 0.03 |
| Pituitary deficiencies | 1.00 | ||
| Hypogonadism | 19 (95) | 19 (95) | |
| Adrenal insufficiency | 15 (75.0) | 16 (80.0) | |
| Central hypothyroidism | 18 (90.0) | 18 (90.0) | |
| GH deficiency | 13 (65.0) | 14 (70.0) | |
| GH deficiency not tested | 2 (10.0) | 1 (5.0) |
Data presented as mean ± SEM or n (%).
Abbreviations: IQR, interquartile range; NA, not applicable; PA, pituitary adenoma.
| Variable . | APD (n = 20) . | CDI (n = 20) . | P Value . |
|---|---|---|---|
| Age at diagnosis, y | 30.7 ± 3.6 | 30.6 ± 2.8 | 0.98 |
| Number of APDs | 3.3 ± 0.2 | 3.4 ± 0.2 | 0.73 |
| Time since first APD, y, [median (IQR)] | 6.8 (4.3) | 12.3 (13.2) | 0.41 |
| Time since CDI, y, [median (IQR)] | NA | 13.3 (16.6) | 0.41 |
| Pituitary tumor | 19 (95.0) | 14 (70.0) | 0.09 |
| Pituitary disease | 0.46 | ||
| Nonfunctioning PA | 5 (25.0) | 4 (20.0) | |
| CP | 4 (20.0) | 5 (25.0) | |
| Prolactinoma | 2 (10.0) | 0 (0) | |
| Acromegaly | 2 (10.0) | 1 (5.0) | |
| Cushing syndrome | 3 (15.0 | 1 (5.0) | |
| Neurosarcoidosis | 0 (0) | 2 (10.0) | |
| Histiocytosis | 0 (0) | 1 (5.0) | |
| Chondrosarcoma | 2 (10.0) | 0 (0) | |
| Pituitary hypoplasia | 1 (5.0) | 1 (5.0) | |
| Pituitary stalk enlargement | 0 (0) | 2 (10.0) | |
| Germinoma | 0 (0) | 2 (10.0) | |
| Other | 1 (5.0) (medulloblastoma) | 1 (5.0) (Rathke cleft cyst) | |
| Macroadenoma | 16 (80.0) | 11 (55.0) | 0.55 |
| Surgery | 17 (85.0) | 13 (65.0) | 0.27 |
| Transsphenoidal surgery | 11 (55.0) | 9 (45.0) | |
| Craniotomy | 4 (20.0) | 4 (20.0) | |
| Both | 2 (10.0) | 0 (0) | |
| Radiotherapy | 15 (75.0) | 5 (35.0) | 0.03 |
| Pituitary deficiencies | 1.00 | ||
| Hypogonadism | 19 (95) | 19 (95) | |
| Adrenal insufficiency | 15 (75.0) | 16 (80.0) | |
| Central hypothyroidism | 18 (90.0) | 18 (90.0) | |
| GH deficiency | 13 (65.0) | 14 (70.0) | |
| GH deficiency not tested | 2 (10.0) | 1 (5.0) |
| Variable . | APD (n = 20) . | CDI (n = 20) . | P Value . |
|---|---|---|---|
| Age at diagnosis, y | 30.7 ± 3.6 | 30.6 ± 2.8 | 0.98 |
| Number of APDs | 3.3 ± 0.2 | 3.4 ± 0.2 | 0.73 |
| Time since first APD, y, [median (IQR)] | 6.8 (4.3) | 12.3 (13.2) | 0.41 |
| Time since CDI, y, [median (IQR)] | NA | 13.3 (16.6) | 0.41 |
| Pituitary tumor | 19 (95.0) | 14 (70.0) | 0.09 |
| Pituitary disease | 0.46 | ||
| Nonfunctioning PA | 5 (25.0) | 4 (20.0) | |
| CP | 4 (20.0) | 5 (25.0) | |
| Prolactinoma | 2 (10.0) | 0 (0) | |
| Acromegaly | 2 (10.0) | 1 (5.0) | |
| Cushing syndrome | 3 (15.0 | 1 (5.0) | |
| Neurosarcoidosis | 0 (0) | 2 (10.0) | |
| Histiocytosis | 0 (0) | 1 (5.0) | |
| Chondrosarcoma | 2 (10.0) | 0 (0) | |
| Pituitary hypoplasia | 1 (5.0) | 1 (5.0) | |
| Pituitary stalk enlargement | 0 (0) | 2 (10.0) | |
| Germinoma | 0 (0) | 2 (10.0) | |
| Other | 1 (5.0) (medulloblastoma) | 1 (5.0) (Rathke cleft cyst) | |
| Macroadenoma | 16 (80.0) | 11 (55.0) | 0.55 |
| Surgery | 17 (85.0) | 13 (65.0) | 0.27 |
| Transsphenoidal surgery | 11 (55.0) | 9 (45.0) | |
| Craniotomy | 4 (20.0) | 4 (20.0) | |
| Both | 2 (10.0) | 0 (0) | |
| Radiotherapy | 15 (75.0) | 5 (35.0) | 0.03 |
| Pituitary deficiencies | 1.00 | ||
| Hypogonadism | 19 (95) | 19 (95) | |
| Adrenal insufficiency | 15 (75.0) | 16 (80.0) | |
| Central hypothyroidism | 18 (90.0) | 18 (90.0) | |
| GH deficiency | 13 (65.0) | 14 (70.0) | |
| GH deficiency not tested | 2 (10.0) | 1 (5.0) |
Data presented as mean ± SEM or n (%).
Abbreviations: IQR, interquartile range; NA, not applicable; PA, pituitary adenoma.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
